Titlebook: Innovative Designs and Analyses for Small Population Clinical Trials; Development Strategi Jingjing Ye,Lei Nie Book 2024 The Editor(s) (if

一再

書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials影響因子(影響力)




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials被引頻次




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials被引頻次學(xué)科排名




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials年度引用




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials年度引用學(xué)科排名




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials讀者反饋




書(shū)目名稱(chēng)Innovative Designs and Analyses for Small Population Clinical Trials讀者反饋學(xué)科排名

Ornament

Master Protocol,e described in detail, separately for exploratory and confirmatory settings. The master protocol has been implemented successfully and improved the patient care in treating patients with rare cancers and pediatric cancers. One of those successful examples is discussed in the chapter.

Magisterial

Operation and Other Considerations,sease classification, and patient monitoring. Additionally, translational relevance of preclinical models to pediatric and rare diseases and potential pharmacodynamic endpoints are included in the considerations.

爭(zhēng)議的蘋(píng)果

Case Studies,ents who receive lung transplants. The third case is Belimumab’s approval that has applied Bayesian analysis to borrow adult data into pediatric to support approval in children with system lupus erythematosus (SLE).

Offensive

Book 2024a systematic framework that depends upon a collaborative infrastructure between the patient community, patient advocacy groups, researchers and investigators, pharmaceutical companies, global regulatory agencies, and customers. The book also highlights the considerations of natural history and patie

Misnomer

責(zé)怪

參考書(shū)目

妨礙

Diagnostic Criteria and Endpoint,tive multi-stake holders’ collaboration to best utilize the available information or generate the fit-for-purpose evidence. The statistical evaluation of the diagnosis and the endpoints are provided. Successful implementations in case studies are included.

habile

Introduction,que rare diseases, affecting 300?million people worldwide, about 72% of which are genetic and about 70% of which are exclusively pediatric onset. More than 90% of rare diseases are without an FDA-approved treatment. Rare diseases are numerous, heterogenous in nature, and geographically disparate. Gi